Together, these data indicate that hypoxia-induced enzyme ERO1α is a novel therapeutic target in pancreatic cancer and a potential biomarker for enabling earlier disease detection and better prediction of clinical course in human patients. Here, ERO1A is linked to pancreatic neoplasm.